Cover Image
市場調查報告書

Risedronate Sodium的中國市場分析

Investigation Report on China Risedronate Sodium Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333639
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Risedronate Sodium的中國市場分析 Investigation Report on China Risedronate Sodium Market, 2010-2019
出版日期: 2015年06月25日 內容資訊: 英文 30 Pages
簡介

在中國隨著人口高齡化,骨質疏鬆症的患者增加,患者數變多,次於心血管疾病。根據統計調查,中國的全國人民的12.4%,50歲以上的女性50%患骨質疏鬆症。Risedronate Sodium是以停經後女性為對象的骨質疏鬆症的預防藥,2004年的階段全球整體達成10億美元以上的銷售額。中國國內的銷售額 (調查樣品醫院的情況) ,從2008年的4萬人民幣以下,2014年達971萬人民幣,以年複合成長率(CAGR)156%達成飛躍性成長。

本報告提供中國的Risedronate Sodium的市場相關分析、整體市場規模趨勢(過去5年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查評估

第1章 Risedronate Sodium的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的Risedronate Sodium市場概況

  • 中國國內的Risedronate Sodium的專利申請、認證情形
  • 主要製造商
  • 市場規模

第3章 Risedronate Sodium銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Risedronate Sodium市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的Risedronate Sodium市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 Risedronate Sodium的醫院用標準價格

  • Kunming Jida Pharmaceutical Co., Ltd
  • Beijing SL Pharm
  • Yangtze River Pharmaceutical Group
  • Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd
  • Topfond (商標名:Weishan)

第7章 中國國內的Risedronate Sodium的主要製造商

  • Beijing SL Pharm
  • Kunming Jida Pharmaceutical Co., Ltd
  • Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd
  • Yangtze River Pharmaceutical Group
  • Topfond

第8章 中國的Risedronate Sodium市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506244

With the ageing population, China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiovascular diseases. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China is 12.4% and that this figure among women aged 50 and above is 50%. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020.

Currently, drugs for the prevention and treatment of osteoporosis are mainly categorized into bone resorption inhibitor which includes diphosphonate (alendronate, etidronate and risedronate), sex hormone, calcitonin, selective estrogen receptor modulator and bone formation promoter, fluoride product, vitamin D and calcium preparation, parathyroid hormone included.

As a member of the new generation of osteoporosis drugs, risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate sodium has brought in a large amount of sales value in the global market, for example, over USD 1 billion in 2004. According to CRI's market survey, risedronate sodium develops fast after appearing in the Chinese market, annual sales value in sample hospitals rising from less than 40,000 in 2008 to CNY 9.71 million in 2014 and CAGR during this period reaching 156%. Risedronate sodiums in the Chinese market are all produced by local enterprises represented by Kunming Jida Pharmaceutical Co., Ltd, Topfond, Yangtze River Pharmaceutical Group, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd and Beijing SL Pharm, among which Kunming Jida Pharmaceutical Co., Ltd has the largest market share of 84% for sales value in 2014.

With the ageing population, the incidence of osteoporosis will continue to grow. Therefore the market size of risedronate sodium is expected to keep expanding fast in the next few years in China.

Readers can get at least the following information from this report:

  • market size of risedronate sodium in China
  • competitive landscape of risedronate sodium in Chinese market
  • price of risedronate sodium made by different enterprises in China
  • market outlook of risedronate sodium in China

The author suggests the following groups of people purchase this report:

  • manufacturers of osteoporosis drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Risedronate Sodium

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Risedronate Sodium in China

  • 2.1. Patent and Approval Status of Risedronate Sodium in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Risedronate Sodium in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Risedronate Sodium in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Risedronate Sodium in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Risedronate Sodium in Chinese Hospitals in 2014

  • 6.1. Kunming Jida Pharmaceutical Co., Ltd
  • 6.2. Beijing SL Pharm
  • 6.3. Yangtze River Pharmaceutical Group
  • 6.4. Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd
  • 6.5. Topfond (Trade Name: Weishan)

7. Major Manufacturers of Risedronate Sodium in Chinese Market, 2010-2014

  • 7.1. Beijing SL Pharm
  • 7.2. Kunming Jida Pharmaceutical Co., Ltd
  • 7.3. Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd
  • 7.4. Yangtze River Pharmaceutical Group
  • 7.5. Topfond

8. Market Outlook of Risedronate Sodium in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Risedronate Sodium in China
  • Chart Sales Status of Risedronate Sodium in China
  • Chart Sales Value of Risedronate Sodium in China, 2010-2014
  • Chart Sales Value of Risedronate Sodium in Some Regions in China, 2010-2014
  • Chart Sales Volume of Risedronate Sodium in China, 2010-2014
  • Chart Sales Value and Market Share of Risedronate Sodium Made by Kunming Jida in China, 2010-2014
  • Chart Sales Value and Market Share of Risedronate Sodium Made by Jiangsu Chiatai Qingjiang in China, 2010-2014
  • Chart Sales Value and Market Share of Risedronate Sodium Made by Beijing SL in China, 2010-2014
  • Chart Sales Value and Market Share of Risedronate Sodium Made by Other Enterprises in China, 2010-2014
  • Chart Sales Value and Market Share of Risedronate Sodium Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Risedronate Sodium Capsules in China, 2010-2014
  • Chart Price of Risedronate Sodium Made by Kunming Jida Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Risedronate Sodium Made by Beijing SL Pharm in Some Chinese Cities in 2014
  • Chart Price of Risedronate Sodium Made by Yangtze River Pharmaceutical Group in Some Chinese Cities in 2014
  • Chart Price of Risedronate Sodium Made by Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Risedronate Sodium Made by Topfond in Some Chinese Cities in 2014
Back to Top